Yellow Fever - Pipeline Insight, 2024

This “Yellow Fever - Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Yellow Fever pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Yellow Fever Understanding

Yellow Fever: Overview

Yellow fever is an acute viral haemorrhagic disease transmitted by infected mosquitoes. The yellow fever virus is an arbovirus of the flavivirus genus and is transmitted by mosquitoes, belonging to the Aedes and Haemagogus species. Yellow fever appears with a sudden onset of fever, chills, headache, backache, nausea, and vomiting. The majority of people infected with yellow fever virus will either not have symptoms, or have mild symptoms and completely recover. Yellow fever is difficult to diagnose, especially during the early stages. More commonly it is diagnosed based on laboratory testing, a person’s symptoms, and travel history. Good and early supportive treatment in hospitals improves survival rates. There is no medicine to treat or cure infection from yellow fever. Vaccination is the most important means of preventing yellow fever.

Yellow Fever - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Yellow Fever pipeline landscape is provided which includes the disease overview and Yellow Fever treatment guidelines. The assessment part of the report embraces, in depth Yellow Fever commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Yellow Fever collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Yellow Fever R&D. The therapies under development are focused on novel approaches to treat/improve Yellow Fever.

Yellow Fever Emerging Drugs Chapters

This segment of the Yellow Fever report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Yellow Fever Emerging Drugs

SP 0218: SanofiSP 0218 is a yellow fever vaccine being developed and investigated in Phase II stage of development. The primary objective of the study is to demonstrate the non-inferiority of the antibody response in terms of seroconversion rate 28 days after vaccine administration of one dose of yellow fever vaccine (vYF) compared to the antibody response after one dose of the YF-VAX control vaccine in yellow fever naïve participants.

TY014: Tysana Pte. Ltd.TY014 is the first monoclonal antibody designed and engineered to treat yellow fever virus infections. TY014 is directed against the envelope (E) protein on the surface of the virus, and prevents viral replication by limiting viral fusion to host cells. Phase I evaluated the Safety and Tolerability of an Antibody against Yellow Fever Virus (TY014) in Humans.

Yellow Fever: Therapeutic Assessment

This segment of the report provides insights about the different Yellow Fever drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Yellow Fever

There are approx. 10+ key companies which are developing the therapies for Yellow Fever. The companies which have their Yellow Fever drug candidates in the most advanced stage, i.e. Phase II include, sanofi.

Phases

This report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Yellow Fever pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Yellow Fever: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Yellow Fever therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Yellow Fever drugs.

Yellow Fever Report Insights

• Yellow Fever Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Yellow Fever Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Yellow Fever drugs?
• How many Yellow Fever drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Yellow Fever?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Yellow Fever therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Yellow Fever and their status?
• What are the key designations that have been granted to the emerging drugs?

This product will be delivered within 2 business days.